TV-46000
Total Payments
$1.9M
Transactions
21
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.9M | 21 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 21 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TV46000-SAD-10055 | Teva Pharmaceuticals USA, Inc. | $1.9M | 0 |
Top Doctors Receiving Payments for TV-46000
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $1.9M | 21 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 0
- Transactions 21
About TV-46000
TV-46000 is a drug associated with $1.9M in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $1.9M was paid across 21 transactions to 0 doctors.
The most common payment nature for TV-46000 is "Unspecified" ($1.9M, 100.0% of total).
TV-46000 is associated with 1 research study, including "TV46000-SAD-10055" ($1.9M).